KRAS‐Mutated, Estrogen Receptor‐Positive Low‐Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery

We report on a woman with aggressive estrogen receptor‐positive, KRAS‐mutated ovarian cancer who achieved a remarkable response to combination therapy with the MEK inhibitor (trametinib) and the aromatase inhibitor (letrozole), even though the disease had failed to respond to a combination of a PI3K...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Kato, Shumei, McFall, Thomas, Takahashi, Kenta, Bamel, Kasey, Ikeda, Sadakatsu, Eskander, Ramez N., Plaxe, Steven, Parker, Barbara, Stites, Edward, Kurzrock, Razelle
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2021
Assuntos:
Precision Medicine Clinic: Molecular Tumor Board
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8018312/
https://ncbi.nlm.nih.gov/pubmed/33528846
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13702
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados